TRIAL DATA
Dual immunotherapy shows promise in mismatch repair proficient colon cancerThe phase 2 NEST trial tested neoadjuvant botensilimab plus balstilimab in patients with resectable colon cancer. The study examined safety, feasibility, and pathologic response before surgical resection. (Clinical Cancer Research)